Search the site

News & Events

RSV responsible for one out of every 50 childhood deaths worldwide

The urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.

News & Events

Australia one step closer to COVID-19 shot for under 5s

Australia’s TGA has granted a provisional determination to Pfizer, allowing the pharmaceutical company to apply for approval to extend its COVID-19 vaccine to children aged 6 mths - 4 yrs.

The PRIME Study

Vaccine Trials Group with Sir Charles Gairdner Hospital is conducting a trial of a vaccine against Clostridium difficile infection (CDI) in at-risk individuals.

Pneumococcal Vaccine Study

Researchers at The Kids Research Institute Australia are studying a new pneumococcal vaccine designed to provide a broader protection for 21 serotypes of the bacteria S. pneumoniae – 8 more serotypes than the current vaccine given to new babies.

VTG Laboratory

Highlights from the VTG Laboratory in 2024

Respiratory Syncytial Virus (RSV)

RSV Protect Study

News & Events

Friendly bacteria reduces flu symptoms and ear infections in mice

Research reveals that friendly bacteria may help reduce flu symptoms, offering new insights into potential treatments and enhancing our understanding of immune health.

News & Events

National-first RSV immunisation program welcomed by The Kids Research Institute Australia

The Kids Research Institute welcomes WA's $11M RSV immunisation program, offering free Nirsevimab to infants, aiming to reduce winter hospitalisations.

News & Events

Study finds high RSV awareness with parents open to future immunisation

A The Kids Research Institute Australia study designed to gauge community awareness of respiratory syncytial virus (RSV) has found parents and parents-to-be are highly aware of the virus and are open to immunisation to tackle it.

News & Events

Study confirms maternal whooping cough vaccine protects babies at critical age

A The Kids Research Institute Australia and Curtin University-led study has found the maternal whooping cough vaccine given to pregnant mothers in the second or third trimester significantly reduced babies’ risk of infection, protecting them at their most vulnerable age.